COLUMBUS, Ohio – The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) announces the following awards, honors, grants and more that were recently given to the organization, teams or individuals: Grants will aid study of novel strategy to enhance immunotherapy in non-small cell lung cancer Researchers at the OSUCCC – James have landed two grants totaling over $900,000 that will help them test a new combination immunotherapy strategy for patients with treatment-resistant non-small cell lung cancer (NSNLC).  Dwight Owen, MD, associate professor in the Division of Medical Oncology, and Xiaopei Huang, PhD, associate professor in the Division of Hematology, will use a $419,000 grant from the National Cancer Institute and a $500,000 grant from the Brown/LUNGevity Foundation to study and target tumor-associated macrophages, or TAMs (a type of white blood cell in the immune system), in a multi-center phase Ib clinical trial. Quiroga and Meng gain NCI K12 career development awards  Dionisia Quiroga, DO, PhD, and Lingbin Meng, MD, PhD, assistant professors in the Division of Medical Oncology, each received a Paul Calabresi Career Development Award for Clinical Oncology (K12) from the National Cancer Institute (NCI). The NCI states that these funding awards are designed “to increase the number of clinicians (MDs, DOs, PharmDs, nurses with PhDs or equivalent) trained in clinical and translational cancer research and to promote their career development.” Dr. Quiroga is a breast medical oncologist and researcher interested in tumor immunology and the role it plays in cancer pathogenesis and treatment. She also studies how fat tissue and the immune system impact breast cancer outcomes to identify new targetable pathways for cancer to be treated. Dr. Meng, a genitourinary medical oncologist, is interested in early-phase clinical trials and translational studies. Her research focuses on overcoming immunotherapy resistance and exploring novel therapeutic approaches for advanced kidney and prostate cancers. Johnson receives travel grant to lecture at ESMO international congress  Kai Johnson, MD, assistant professor in the Division of Medical Oncology, received a Merit Travel Grant to present a lecture at the European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress, which was held May 14-17 in Munich, Germany. His presentation was titled “Role of Oncotype DX Risk Categorization & Receipt of Chemotherapy on Survival Outcomes Among Men with Node-Positive (pN1) Hormone Receptor Positive (HR+) Breast Cancer.” Dr. Johnson treats patients with breast cancer, including its aggressive and rare forms. His research is focused on developing therapies to improve outcomes for patients with various breast malignancies – including metastatic triple-negative breast cancer – with a combination of targeted agents, immunotherapy and tumor-ablation techniques.  Memmott accepted to attend AAMC women faculty leadership development seminar  Regan Memmott, MD, PhD, assistant professor in the Division of Medical Oncology, was accepted to attend the Association of American Medical Colleges (AAMC) 2025 Early-Career Women Faculty Leadership Development Seminar in July. The seminar provides faculty members at the assistant professor level with foundational leadership knowledge and skills to help them thrive as leaders in academia and science. Dr. Memmott also is in the Translational Therapeutics Program at the OSUCCC – James, where her research focuses on identifying biological mechanisms by which lung cancer may resist targeted therapies, and on developing strategies to help patients overcome those mechanisms.